Do beta-blockers prevent contralateral breast cancer development?
Denmark: According to a new study, women with breast cancer did not have a protective impact of beta-blocker usage on the incidence of contralateral breast cancer (CBC), regardless of beta-blocker type. This study was conducted by Mathilde Gottschau and the team. The results of this work were published in the International Journal of Cancer on 5th January 2022.
Beta-blockers, commonly known as beta-adrenergic blocking agents, are blood pressure medications. Beta-blockers cause your heart to beat more slowly and forcefully. Antagonism of 2-adrenergic signaling has been shown in preclinical investigations to block numerous pathways required for breast tumor development and metastasis. A number of population-based observational studies were carried out to investigate the relationships between beta-blocker use and breast tumor features at diagnosis.
Researchers used countrywide Danish health registrations and the Danish Breast Cancer Group database to assess post-diagnosis beta-blocker usage and risk of CBC in a cohort of 52 723 women with breast cancer for this study. Post-diagnosis beta-blocker usage was characterized as a time-varying covariate beginning one year after a second prescription was redeemed. The Cox proportional hazards regression method was used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with beta-blocker usage versus non-use.
The key findings of this study are as follow:
1. A total of 1444 women with CBC were identified, with 209 of them using beta-blockers.
2. There was an overall HR of 1.08 for beta-blocker usage and CBC risk, with no significant difference according to cumulative quantity, intensity, or selectivity of beta-blocker use.
In conclusion, the data laid out in this study positively indicates the point that there is no such evident effect of beta-blockers be it in terms of positive or negative impact on contralateral breast cancer. Further studies are required for more conclusive data, added the Authors.
Reference:
Gottschau, M., Bens, A., Friis, S., Cronin-Fenton, D., Aalborg, G.L., Jensen, M.-B., Ejlertsen, B., Kroman, N. and Mellemkjær, L. (2022), Use of beta-blockers and risk of contralateral breast cancer. Int. J. Cancer. Accepted Author Manuscript. https://doi.org/10.1002/ijc.33923
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.